logo
Stop Gas Station Heroin Coalition Commends FDA Crackdown on Illegal Drug '7'

Stop Gas Station Heroin Coalition Commends FDA Crackdown on Illegal Drug '7'

Associated Press12 hours ago
Agency enforcement targets lab-made analogs, protecting consumers from unapproved new drugs
The Stop Gas Station Heroin coalition today commended the U.S. Food and Drug Administration (FDA) for issuing warning letters to companies marketing '7" — a dangerous semi-synthetic alkaloid often disguised as a natural dietary supplement.
This action marks a critical step toward curbing the spread of " Gas Station Heroin " — a term used to describe a range of often imported lab-made substances that include tianeptine, nitrous oxide, semi-synthetic and synthetic alkaloid products, and intoxicating hemp products.
7-hydroxymitragynine (7-OH) is only naturally present in trace amounts in dried kratom leaves. Bad actors synthetically mass produce high-concentration, ultra-potent 7-OH isolates in tablets, capsules, powders, and gummies. These chemically manipulated products are misleadingly marketed as natural dietary supplements or food. In reality, they act like prescription opioids and not botanicals, posing serious health risks such as respiratory depression, addiction, and overdose.
The FDA's warning letters underscore what scientists and public health experts have long known: Gas Station Heroin products are not supplements. They are unapproved, mislabeled street drugs designed to mimic the effects of opioids and other narcotics.
As the FDA notes, Gas Station Heroin products are often aggressively advertised online and in retail locations with deceptive claims about their safety and effectiveness, particularly to individuals seeking to get high or prescription alternatives for pain relief, anxiety, or opioid withdrawal.
Stop Gas Station Heroin applauds the FDA for using its enforcement authority to hold these illicit companies accountable and to protect American consumers from the growing threat posed by synthetic drugs.
About Stop Gas Station Heroin
Stop Gas Station Heroin is a national coalition that aims to educate consumers about harmful synthetic drugs and advocate for smart regulation that distinguishes between legitimate, natural botanicals and dangerous, synthetic drugs, combined with enforcement of current federal laws around unapproved drugs. To learn more, navigate to stopgasstationheroin.com.
Media Contact
Colby Wilson
[email protected]
###
SOURCE: Stop Gas Station Heroin
Copyright 2025 EZ Newswire
https://app.eznewswire.com/news/stop-gas-station-heroin-coalition-commends-fda-crackdown-on-drug-7
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dr. Michael Rimlawi Announces National Scholarship for Aspiring Physicians, Supporting Future Leaders in Medicine
Dr. Michael Rimlawi Announces National Scholarship for Aspiring Physicians, Supporting Future Leaders in Medicine

Yahoo

time19 minutes ago

  • Yahoo

Dr. Michael Rimlawi Announces National Scholarship for Aspiring Physicians, Supporting Future Leaders in Medicine

Dr. Michael Rimlawi DALLAS, July 17, 2025 (GLOBE NEWSWIRE) -- The Dr. Michael Rimlawi Scholarship for Future Doctors proudly announces its 2026 application cycle, inviting undergraduate students with aspirations of entering the medical field to apply. Established by renowned spine surgeon Dr. Michael Rimlawi, the scholarship aims to recognize and encourage promising future physicians who are committed to improving healthcare through compassion, innovation, and excellence. The Dr. Michael Rimlawi Scholarship for Future Doctors is open to undergraduate students enrolled at accredited colleges or universities across the United States who are pursuing a career in medicine. Applicants are required to submit an original and thoughtful essay responding to the following prompt: 'What inspired you to pursue a career in medicine, and how do you hope to make a difference in the field?' Essays must be between 500 and 750 words, reflecting a genuine passion for medicine and a clear vision for contributing to the healthcare profession. Dr. Michael Rimlawi, who serves as the driving force behind this initiative, believes that encouraging the next generation of doctors is vital for the continued advancement of patient care and medical practice. Dr. Michael Rimlawi is widely recognized for his groundbreaking work in minimally invasive spine surgery. Combining orthopedic and neurosurgical principles, Dr. Michael Rimlawi has developed and performed transformative procedures designed to reduce recovery times and enhance surgical accuracy. His role as the first surgeon in the United States to carry out the Globus Minimally Invasive XLIF procedure highlights his commitment to medical progress. In addition to his work in the operating room, Dr. Michael Rimlawi is dedicated to mentoring emerging medical professionals. Through the Dr. Michael Rimlawi Scholarship for Future Doctors, he seeks to nurture those who display both academic potential and a sincere dedication to advancing the quality of care for patients. This one-time award provides meaningful support to help offset educational expenses and encourage continued academic success. The application window is open now, with a submission deadline of January 15, 2026. The scholarship winner will be formally announced on February 15, 2026, following a careful review of all eligible essays. The Dr. Michael Rimlawi Scholarship for Future Doctors does not place any restrictions based on city or state, offering a national opportunity to talented students across the country. By supporting these aspiring physicians, Dr. Michael Rimlawi continues his mission to advance the future of medicine beyond his surgical practice. For undergraduate students who dream of becoming doctors, the Dr. Michael Rimlawi Scholarship for Future Doctors represents not only financial assistance but also the support of a leader who has dedicated his life to raising the standards of healthcare. Applicants are encouraged to visit the scholarship's website for complete details and submission guidelines. Contact Information: Spokesperson: Dr. Michael RimlawiOrganization: Dr. Michael Rimlawi Scholarship for Future DoctorsWebsite: apply@ A photo accompanying this announcement is available at

Waud Capital Partners Forms New Partnership with Experienced Healthcare Executive Bill Mixon
Waud Capital Partners Forms New Partnership with Experienced Healthcare Executive Bill Mixon

Yahoo

time19 minutes ago

  • Yahoo

Waud Capital Partners Forms New Partnership with Experienced Healthcare Executive Bill Mixon

Waud Capital Partners teams up with accomplished industry executive to acquire and build a healthcare supply chain solutions company CHICAGO, July 17, 2025 /PRNewswire/ -- Waud Capital Partners ("Waud Capital"), a growth-oriented middle-market private equity firm, announced today that it has formalized an executive partnership with Bill Mixon to pursue a platform investment in the medical device and supply chain services market. Targeted sub-sectors of focus will include but are not limited to home distribution, other value-add specialty distribution, outsourced provider equipment services, and chronic care and population health management offerings that deliver value to supply chain channel partners. Waud Capital anticipates investing over $100 million of equity capital to support the initiative. Mr. Mixon is an accomplished healthcare executive with more than 30 years of operating experience across the medical device and supply chain services continuum, with particular emphasis on specialty distribution and outsourced provider equipment services. He brings deep operational expertise with an extensive focus on enhancing clinical value and improving patient outcomes through the medical supply chain. Mr. Mixon has successfully scaled several private equity-backed and publicly traded organizations through repeatable organic growth strategies as well as strategic acquisitions. Most recently, Mr. Mixon served as Chief Executive Officer of Advanced Diabetes Supply, where he led the organization through a successful sale from its private equity sponsor to Cardinal Health. Advanced Diabetes Supply is a national diabetes care management platform distributing innovative therapies including continuous glucose monitors and other diabetes-related supplies. During his time at Advanced Diabetes Supply, Mr. Mixon drove transformational growth by professionalizing the organization through salesforce productivity enhancements, executing a shift in go-to-market initiatives, and delivering margin improvements through revenue cycle initiatives and other operational efficiencies. At time of sale to Cardinal Health, Advanced Diabetes Supply had grown to $1B in revenue and served nearly a half-million patients annually. Prior to Advanced Diabetes Supply, Mr. Mixon was the Chief Executive Officer of National Seating & Mobility, a provider of comprehensive mobility solutions to patients in the home. Under Mr. Mixon's leadership at National Seating & Mobility, the organization scaled through organic and inorganic methods and successfully transacted on several different occasions to multiple private equity sponsors. Mr. Mixon began his career with the U.S. Army before holding leadership positions at large organizations such as Baxter, Phillips, and Agiliti Health. "I'm excited to partner with Waud Capital to identify and help build what we hope will be an industry-leading business that supports and improves the overall healthcare supply chain," said Mr. Mixon. "Waud Capital's executive partnership approach, dedicated ecosystem resources, and deep investing experience across relevant areas make the firm a highly attractive partner. I believe this combination will enable us to capitalize on transformative growth opportunities, and I look forward to leveraging my past experiences to drive clinical value for medical professionals, manufacturers, payors and most importantly, patients." "We are thrilled to partner with Bill," said Mike Lehman, Principal at Waud Capital. "He is an exceptional executive who has created value and driven multiple successful outcomes throughout his career in a sector we find highly attractive. The healthcare supply chain markets are highly fragmented with significant opportunities for organizations to deliver value-add solutions and address substantial challenges for key stakeholders." This executive partnership builds upon Waud Capital's extensive experience investing across the broader healthcare supply chain services and home care markets. Notable investments include Mopec Group (supplier of pathology equipment, consumables and services), PromptCare (home infusion and durable medical equipment), Provider Network Holdings (specialty medication supply management), DS Medical (home medical supplies), and recent home care investments AltoCare (in-home senior care), and Concierge Home Care (skilled home healthcare). "The partnership with Bill is another example of Waud Capital's executive-first campaign approach and commitment to support accomplished executive leaders with the full ecosystem of resources to execute transformative growth strategies in large, growing markets," said Kyle Lattner, Partner at Waud Capital. "This is our second dedicated campaign in the medical device and supply chain services market in the last two years and we are thrilled about the prospects of what we can accomplish during our partnership with Bill." About Waud Capital PartnersBased in Chicago and founded by Reeve B. Waud, Waud Capital Partners is a growth-oriented private equity firm with over 30 years of investing experience. Waud Capital Partners seeks to partner with experienced management teams to build market-leading companies within two industries: healthcare and software & technology. Since its founding in 1993, Waud Capital has successfully completed more than 500 investments, including platform companies and follow-on opportunities. For additional information on Waud Capital, please visit Investment Professional Contacts:Kyle Lattner, Partner(312) 676-8404klattner@ Mike Lehman, Principal(312) 676-8446mlehman@ Business Development Contact:Phil Olson, Partner – Business Development(312) 676-8401polson@ Investor Relations Contact:Jessica Schmitt, Head of Investor Relations(312) 676-8400jschmitt@ View original content to download multimedia: SOURCE Waud Capital Partners

Deodorant sold by Walmart, Amazon recalled nationwide
Deodorant sold by Walmart, Amazon recalled nationwide

The Hill

time20 minutes ago

  • The Hill

Deodorant sold by Walmart, Amazon recalled nationwide

(NewsNation) — Over 67,000 cases of three types of Power Stick deodorant have been recalled due to ' cGMP deviations,' meaning the product did not meet manufacturing regulations by the Food and Drug Administration (FDA). According to an FDA enforcement report, A.P. Deauville initiated the recall on July 10 for 67,214 cases of Power Stick for Her roll-on Antiperspirant Deodorant Powder Fresh, Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh and Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant. The lot numbers of the recalled deodorant, according to the report, are: Power Stick for Her Roll-On: 032026B011, 032226B031, 051626C241, 061526C882, 071226D371, 071226D381, 082526E341 and 082826E402. Power Stick Invisible Protection Roll-On: 031726A991, 041226B561, 062026C901, 062026C911, 071026D351, 071026D361, 071326D391 and 111626G231. Power Stick Original Nourishing Invisible Protection Roll-On: 101225D781, 032926B281, 032826B221, 041126B531, 062226D011, 070626D301, 070626D333, 111026G051, 111326G091 and 111626G221. The antiperspirants were distributed nationwide and sold at Walmart, Amazon and Dollar Tree.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store